Literature DB >> 10963116

Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma.

E Ioachim1, A Charchanti, N E Stavropoulos, A Skopelitou, E D Athanassiou, N J Agnantis.   

Abstract

Archival biopsy specimens from transitional cell bladder cancers (n=88) were analysed immunohistochemically for the expression of the retinoblastoma (Rb) gene protein, p53, mdm2, c-erbB-2, HLA-DR antigen and proliferation indices. An altered nuclear expression of Rb, p53 and mdm2 was observed in 55.2%, 33.3% and 18.2% of tumors respectively. Cytoplasmic membrane immunoreactivity (>25% tumor cells) for c-erbB-2 was detected in 14.1% of tumors and aberrant HLA-DR antigen cytoplasmic staining (>5% of tumor cells) in 22.2% of the cases. P53 overexpression was associated with higher tumor grade and stage. Aberrant HLA-DR antigen expression and PCNA were also correlated with the grade of differentiation and tumor stage. MIB1 was statistically correlated with stage. pRb scores and HLA-DR antigen expression were correlated with proliferation activity as determined by PCNA and MIB1 immunostaining. p53 protein was also strongly correlated with the proliferation index PCNA. A strong correlation between PCNA and MIB1 (p<0.0001) was also found. In addition a statistically positive correlation between p53 and HLA-DR antigen expression was observed. Our data show that, although pRb and p53 protein expressions are not associated between them, they may contribute to the growth fraction of the bladder cancer. In addition, p53 and HLA-DR antigen expression could be indicators of aggressive behavior of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10963116     DOI: 10.14670/HH-15.721

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  5 in total

Review 1.  New and promising strategies in the management of bladder cancer.

Authors:  Andrea B Apolo; Nicholas J Vogelzang; Dan Theodorescu
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

2.  Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma.

Authors:  Gonzague de Pinieux; Delphine Colin; Anne Vincent-Salomon; Jérôme Couturier; Delphine Amsellem-Ouazana; Philippe Beuzeboc; Annick Vieillefond
Journal:  Virchows Arch       Date:  2004-03-17       Impact factor: 4.064

3.  Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer.

Authors:  Hussein M Khaled; Abeer A Bahnassy; Amira A Raafat; Abdel-Rahman N Zekri; Maha S Madboul; Nadia M Mokhtar
Journal:  BMC Cancer       Date:  2009-01-26       Impact factor: 4.430

4.  Characterization and Molecular Mechanism of Peptide-Conjugated Gold Nanoparticle Inhibiting p53-HDM2 Interaction in Retinoblastoma.

Authors:  Sushma Kalmodia; Sowmya Parameswaran; Kalaivani Ganapathy; Wenrong Yang; Colin J Barrow; Jagat R Kanwar; Kislay Roy; Madavan Vasudevan; Kirti Kulkarni; Sailaja V Elchuri; Subramanian Krishnakumar
Journal:  Mol Ther Nucleic Acids       Date:  2017-10-20

5.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.